- Home
- RXO vs ELVN Comparison
RXO vs ELVN Comparison
Compare RXO & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXO | ELVN |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.2B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RXO | ELVN |
|---|---|---|
| Price | $19.97 | $46.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | $16.33 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.81 | 3.17 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,742,000,000.00 | N/A |
| Revenue This Year | $0.49 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.20 | N/A |
| 52 Week Low | $10.43 | $14.79 |
| 52 Week High | $29.90 | $62.32 |
Technical Indicators
Market Signals| Indicator | RXO | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | N/A |
| Support Level | $19.08 | N/A |
| Resistance Level | $20.19 | N/A |
| Average True Range (ATR) | 0.94 | 0.00 |
| MACD | 0.13 | 0.00 |
| Stochastic Oscillator | 47.94 | 0.00 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.